06:10 AM EDT, 04/08/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Sunday that a phase 2 study evaluating the investigational drug zilebesiran in treating hypertension has met its primary endpoint.

Zilebesiran reached the study's primary endpoint after demonstrating statistically significant reductions in systolic blood pressure in three months, the company said.

"Most laboratory abnormalities of interest were mild, occurred in the first three months of treatment and resolved upon repeat measure within one to two weeks without intervention," the company said, adding that no adverse events led to study discontinuation.

The study evaluated adding zilebesiran to standard-of-care antihypertensive medications in adults with mild-to-moderate hypertension, according to the company.

Price: 153.66, Change: +0.1, Percent Change: +0.07